Case Report: Patient-derived organoids guiding dabrafenib–trametinib therapy in BRAFV600E-mutant metastatic gastric cancer

BackgroundBRAFV600E mutations occur in approximately 0.4% of gastric cancer (GC) cases and are associated with aggressive disease and limited therapeutic options. Cytotoxic chemotherapy remains the standard first-line treatment for this rare molecular subtype, while evidence-based targeted strategie...

Descripció completa

Dades bibliogràfiques

Autors principals:	Caifeng Gong, Yang Yang, Qi Yan, Weiting Zhao, Minghao Zhang, Wen Zhang, Shuhui You, Ruihong Yin, Yang Huang, Yunshan Zhao, Aiping Zhou
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-05-01
Col·lecció:	Frontiers in Oncology
Matèries:	BRAF kinase inhibitor organoids preclinical model stomach neoplasms targeted therapy
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1813652/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!